Menopause therapy options (2026 reference)
Reference snapshot of approved and emerging menopause therapy options.
Approved menopause therapy in 2026: hormone therapy (estrogen +/- progestogen, multiple delivery formats), non-hormonal vasomotor agents (NK3 receptor antagonist fezolinetant, plus follow-on entrants), low-dose paroxetine, vaginal estrogen and DHEA for genitourinary symptoms.
Late-stage pipeline includes additional NK3 antagonists, novel GnIH-pathway agents, and selective estrogen pathway modulators. Cognitive and cardiovascular benefit framing remains contested in the evidence base.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.